Phase 1 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with one of the following cancers that has come back or stopped responding to treatment: rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor
- People whose cancer has not responded to, has returned after, or still shows signs of disease following standard treatments, or where standard treatments cannot be used due to serious side effects or medical reasons
- People whose cancer can be measured or detected on scans after their most recent treatment
- People aged 1 year and older, but under 24 years old
- People who weigh more than 10 kg (approximately 22 pounds)
- People who have not taken steroid medications (taken by mouth or injection) in the week before the cell collection procedure
- People with a performance score of 60 or above on the Karnofsky or Lansky scale, meaning they are able to carry out at least some normal activities (confirm with trial site)
- People of childbearing potential or those capable of fathering a child who agree to use effective contraception throughout the trial and for 6 months after receiving the treatment
- People whose blood counts meet the required minimums: white blood cell counts (ANC above 500, and lymphocytes above 1,000 per microlitre), and platelets above 50,000 per microlitre (which may be achieved with a transfusion)
- People whose liver function tests are within acceptable ranges (bilirubin no higher than 2.5 mg/dL, and liver enzymes no more than 5 times the normal limit for their age)
- People whose kidney function is within acceptable ranges based on age and sex, or whose kidney filtration rate is at least 70 mL/min/1.73m²
- People who test negative for pregnancy (where applicable)
- People with blood oxygen levels above 90% while breathing normal room air
- People with adequate heart function, shown by specific measurements on an echocardiogram or heart scan (confirm with trial site for exact values)
- People with no significant neurological side effects from prior treatment, with the exception of mild nerve-related sensory symptoms or a seizure disorder that is well controlled with medication
- People for whom enough time has passed since their last cancer treatment before the cell collection — specific waiting periods apply depending on the type of treatment previously received (confirm with trial site for the exact timeframes that apply)
- A patient, parent, or guardian who is able to give informed consent
Who may not be able to join:
- People who have cancer that has spread to the brain or central nervous system
- People with an infection that is not under control, or people known to have HIV
- People who are pregnant or breastfeeding
- People who have previously received a bone marrow or stem cell transplant from another person (allogeneic transplant)
- People with a serious illness or medical condition that could interfere with assessing the safety or effectiveness of the treatment
- People who have had radiation to the whole lung or chest area (mediastinum) within the past 12 weeks (this applies at the time of treatment infusion)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Holly Meany, MD, Children's National Research Institute
Phone: 2024765697
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Grade 3 or more immediate infusion-related adverse event; Grade 4 or more Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS); Grade 3 neurotoxicity or ICANS persisting for more than 72 hours; Grade 4 or more Cytokine Release Syndrome (CRS); Grade 3 Cytokine Release Syndrome (CRS) lasting more than 14 days; Grade 3 or more Hemophagocytic Lymphohistiocytosis (HLH); Grade 3 or more fever lasting for more than 14 days; Grade 4 or more infection uncontrolled for more than 7 days; Any unexpected toxicity of Grade 2 or more; Any expected toxicity above Grade 4; Any expected toxicity above...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.